ERBB2 and breast cancer: Moreover, it was found that trastuzumab (TRA) and lapatinib (LAP) treatments in human epidermal growth factor receptor 2 positive (HER2 +) BC cells blocked phosphoinositide 3-kinase (PI3K) pathway resulting in high miR-16 levels.